Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
23/09/2026 12:04
BRIEF-Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus Roivant Sciences Ltd ROIV.O:
ROIVANT ANNOUNCES TOPLINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF IMVT-1402 IN CUTANEOUS LUPUS ERYTHEMATOSUS
ROIVANT SCIENCES - IMVT-1402 STUDY IN CLE DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
ROIVANT SCIENCES - IMMUNOVANT TO STOP DEVELOPMENT OF IMVT-1402 IN CLE
ROIVANT SCIENCES - IMVT-1402 DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
ROIVANT SCIENCES - ALL OTHER CLINICAL DEVELOPMENT TIMELINES REMAIN ON TRACK
Source text: ID:nGNX559XzF
Further company coverage: ROIV.O
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple